Adtalem (ATGE) Q2 2026 earnings review
Walden Sprints, Chamberlain Stumbles, Buybacks Explode
Adtalem delivered a robust double-beat, with Revenue up 12% and Adjusted EPS surging 34%. However, the headline strength masks a sharp divergence: Walden University is practically carrying the entire company (Revenue +27%), while the flagship Chamberlain University shrank in enrollment (-1%) and saw profits dive (-14%). Management is masking this operational mixed bag with aggressive capital allocation, launching a massive $750M share repurchase program. While the FY26 EPS guidance raise is encouraging, the reliance on a single segment to offset weakness elsewhere is a structural risk.
🐂 Bull Case
Walden University revenue jumped 27% (16.5% organic, excluding calendar shift), driving a 66% explosion in Segment Adjusted EBITDA. Enrollment grew 13%, marking the tenth consecutive quarter of gains.
Management signaled massive confidence by authorizing a new $750M share repurchase program through 2028. For context, they repurchased $165M in Q2 alone.
🐻 Bear Case
The nursing segment is struggling. Enrollment turned negative (-1.0%) for the first time in years, and Adjusted Operating Income fell 20%. The 'execution failures' noted in Q1 have not yet been resolved.
A calendar shift moved $18M of revenue into this quarter for Walden. Without this one-time anomaly, consolidated revenue growth would have been 8.4% rather than the reported 12.4%.
⚖️ Verdict: 🟢
Bullish. Despite the concerning stumble at Chamberlain, the financial engine at Walden is firing on all cylinders, generating enough cash to fund a massive buyback program. The EPS guidance raise confirms that the sum of the parts is working, even if one part needs repair.
Key Themes
Walden: The Profit Engine
Walden is currently the company's MVP. Revenue surged 27% YoY to $217.6M. Even stripping out the $18M beneficial academic calendar shift, organic growth was a healthy 16.5%. More importantly, operational leverage is kicking in: Adjusted EBITDA for the segment leaped 66.5% to $86.7M. High enrollment growth (+13%) proves the 'Growth with Purpose' strategy is resonating here.
Chamberlain's Margin Compression
Reversing. Chamberlain was historically a growth driver, but it has hit a wall. Revenue was flat (+1.6%), but profitability collapsed. Adjusted EBITDA fell 14% YoY, and margins contracted from 29.1% (25Q2) to 24.6% (26Q2). Management blames post-licensure nursing declines, but the magnitude of the profit drop suggests rising customer acquisition costs or fixed cost inefficiencies.
Capital Allocation Overdrive
Adtalem is aggressively buying its own stock. They completed a $150M program in December 2025 and immediately authorized a new $750M program. In Q2 alone, they bought back $165M. With net leverage at a very comfortable 0.9x, they have significant runway to support the stock price through buybacks.
Medical & Veterinary Steady Improvement
Stable. The Med/Vet segment is quietly performing well. Revenue grew 6.9% and enrollment was up 2.4%. While not explosive like Walden, it is a consistent contributor, with EBITDA up 17.6% YoY. This stability provides a floor while Chamberlain undergoes repairs.
Tax Rate Headwind
While operating income is strong, the Provision for Income Taxes increased significantly to $25.7M (from $21.0M YoY). The effective tax rate is creeping up, partially offsetting operational gains. This was flagged in previous quarters but is now materializing in the P&L.
Other KPIs
Accelerating. Up significantly from 27.9% in the prior year period. This expansion is driven entirely by Walden's 66% profit jump, which masked the 14% profit decline at Chamberlain.
Decelerating. Growth slowed to +6.3% YoY, down from +8.0% in Q1 and +10.2% in Q4. While still positive (10th consecutive quarter), the trajectory is cooling due to Chamberlain's contraction.
Derived (Op Cash Flow Continuing Ops $160.1M - CapEx $30.6M). Strong generation supports the buyback thesis. Cash balance is $56M, down from $199M in June due to heavy debt repayment and buybacks.
Guidance
Accelerating. Raised from prior guidance of $7.60 - $7.90. The new midpoint ($7.90) implies ~18.5% YoY growth. This reflects confidence in Walden's continued strength offsetting Chamberlain's weakness.
Stable. Guidance range maintained. Implies 6.0% - 8.5% YoY growth. The fact that revenue guidance was NOT raised despite the Q2 beat suggests management expects the second half to be softer, likely due to the reversal of Walden's timing benefit.
Key Questions
Chamberlain Turnaround Timeline
Chamberlain enrollment has flipped from +11.5% growth a year ago to -1.0% decline today. Is this the bottom, or should we expect further contraction in Q3 before the 'fix' takes hold?
Post-Shift Walden Sustainability
Walden benefited from an $18M calendar shift this quarter. Once that normalizes in Q3, what is the sustainable organic growth rate for this segment? Can it maintain double-digits?
Buyback Pacing
You authorized a massive $750M buyback. With $165M deployed in Q2 alone, do you intend to front-load this program in FY26, or will it be spread evenly through 2028?